SCHEMBL4555993

SCHEMBL4555993

Cn1c(S(=O)(=O)O)cc2cc(F)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
LMNA P02545 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
IDO1 P14902 1/20 0.40
TP53 P04637 2/20 0.36
POLB P06746 1/20 0.36
ACSS2 Q9NR19 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
PTGS2 P35354 1/20 0.35
HCRTR1 O43613 1/20 0.35
KCNH2 Q12809 1/20 0.35
CA2 P00918 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2113343 0.83 ALDH1A1 (0.51) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4556009 0.77 DAO (0.51) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL2732524 0.71 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL986506 0.71 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL1272871 0.71 ALDH1A1 (0.49) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL8040679 0.71 ALDH1A1 (0.56) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL3058667 0.70 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL28386868 0.70 CA2 (0.44) HPGDHSD17B10LMNACA2
SCHEMBL4744999 0.70 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL1272869 0.70 ALDH1A1 (0.48) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-07-10 US claimed
CN-101578265-B Sulfonamide derivatives as chymase inhibitors HOFFMANN LA ROCHE 2013-05-08 CN disclosed
EP-2118062-A1 SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-11-18 EP disclosed
CN-101578265-A Sulfonamide derivatives as chymase inhibitors HOFFMANN LA ROCHE (CH) 2009-11-11 CN disclosed
WO-2008084004-A1 SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-17 WO disclosed
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167348-A1 NOVEL SULFONAMIDE DERIVATIVES CMA1, ARSA, TPSAB1 KDM4E 2315/4885ALDH1A1 1277/4885HPGD 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.